Chapter 50. Evidence-Based Review of Therapies in Multiple Myeloma
- Mark A. Crowther MD, MSc, FRCPC Professor Division Director3,4,
- Jeff Ginsberg MD, FRCPC Professor5,
- Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor6,7,
- Ralph M. Meyer MD, FRCPC Director Professor8,9 and
- Richard Lottenberg MD, FACP Professor10
Published Online: 4 FEB 2009
Copyright © 2008 Blackwell Publishing Ltd
How to Cite
Sebag, M. and Stewart, A. K. (2008) Evidence-Based Review of Therapies in Multiple Myeloma, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch50
Division of Hematology, McMaster University, Hamilton, Ontario, Canada
St. Joseph's Hospital, Hamilton, Ontario, Canada
Department of Medicine, McMaster University, Hamilton, Canada
CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy
McMaster University, Hamilton, Canada
National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada
Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada
Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA
- Published Online: 4 FEB 2009
- Published Print: 27 JUN 2008
Print ISBN: 9781405157476
Online ISBN: 9781444300857
- Multiplemyeloma (MM) - second most common hematological malignancy in adults;
- literature-search strategy and inclusions;
- therapies in multiple myeloma;
- Phase III Trials comparing stem cell transplantation with conventional chemotherapy;
- high dose therapy followed by stem cell transplant and improved outcomes;
- lactate dehydrogenase (LDH);
- bortezomib superior to dexamethasone in relapsed/refractory myeloma;
- lenalidomide role in patients with relapsed or refractory myeloma
This chapter contains sections titled:
Literature-search strategy and inclusions
In patients who are to undergo autologous transplantation as initial therapy is dexamethasone with thalidomide superior to dexamethasone alone as initial therapy for untreated multiple myeloma?
Does the addition of thalidomide to melphalan and prednisone improve outcomes in untreated patients?
Does high dose therapy followed by stem cell transplant improve outcomes compared with conventional therapy?
Is bortezomib superior to dexamethasone in relapsed/refractory myeloma?
What is the role of lenalidomide in patients with relapsed or refractory myeloma?